<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35393544</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>06</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1476-5594</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>41</Volume>
            <Issue>17</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Oncogene</Title>
          <ISOAbbreviation>Oncogene</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Malignant peripheral nerve sheath tumor: models, biology, and translation.</ArticleTitle>
        <Pagination>
          <StartPage>2405</StartPage>
          <EndPage>2421</EndPage>
          <MedlinePgn>2405-2421</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41388-022-02290-1</ELocationID>
        <Abstract>
          <AbstractText>Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive, invasive cancer that comprise around 10% of all soft tissue sarcomas and develop in about 8-13% of patients with Neurofibromatosis Type 1. They are associated with poor prognosis and are the leading cause of mortality in NF1 patients. MPNSTs can also develop sporadically or following exposure to radiation. There is currently no effective targeted therapy to treat MPNSTs and surgical removal remains the mainstay treatment. Unfortunately, surgery is not always possible due to the size and location of the tumor, thus, a better understanding of MPNST initiation and development is required to design novel therapeutics. Here, we provide an overview of MPNST biology and genetics, discuss findings regarding the developmental origin of MPNST, and summarize the various model systems employed to study MPNST. Finally, we discuss current management strategies for MPNST, as well as recent developments in translating basic research findings into potential therapies.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s), under exclusive licence to Springer Nature Limited.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Somatilaka</LastName>
            <ForeName>Bandarigoda N</ForeName>
            <Initials>BN</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, 75390-9069, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sadek</LastName>
            <ForeName>Ali</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, 75390-9069, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McKay</LastName>
            <ForeName>Renee M</ForeName>
            <Initials>RM</Initials>
            <Identifier Source="ORCID">0000-0001-5976-1996</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, 75390-9069, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Le</LastName>
            <ForeName>Lu Q</ForeName>
            <Initials>LQ</Initials>
            <Identifier Source="ORCID">0000-0003-2817-5382</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, 75390-9069, USA. lu.le@utsouthwestern.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, 75390-9069, USA. lu.le@utsouthwestern.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>UTSW Comprehensive Neurofibromatosis Clinic, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, 75390-9069, USA. lu.le@utsouthwestern.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Hamon Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, 75390-9069, USA. lu.le@utsouthwestern.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>O'Donnell Brain Institute, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, 75390-9069, USA. lu.le@utsouthwestern.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 CA166593</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U54 CA196519</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Oncogene</MedlineTA>
        <NlmUniqueID>8711562</NlmUniqueID>
        <ISSNLinking>0950-9232</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001695" MajorTopicYN="N">Biology</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018317" MajorTopicYN="Y">Nerve Sheath Neoplasms</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009456" MajorTopicYN="Y">Neurofibromatosis 1</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018319" MajorTopicYN="Y">Neurofibrosarcoma</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012509" MajorTopicYN="Y">Sarcoma</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement><b>Conflicts of interest:</b> The authors have declared that they
have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2022</Year>
          <Month>10</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>8</Day>
          <Hour>5</Hour>
          <Minute>31</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35393544</ArticleId>
        <ArticleId IdType="mid">NIHMS1791506</ArticleId>
        <ArticleId IdType="pmc">PMC9035132</ArticleId>
        <ArticleId IdType="doi">10.1038/s41388-022-02290-1</ArticleId>
        <ArticleId IdType="pii">10.1038/s41388-022-02290-1</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Holt GR. Von Recklinghausen’s
neurofibromatosis. Otolaryngol Clin North Am
1987; 20:
179–193.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3104862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bos JL, Rehmann H, Wittinghofer A. GEFs and GAPs: critical elements in the control of small
G proteins. Cell
2007; 129:
865–877.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17540168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stalnecker CA, Der CJ. RAS, wanted dead or alive: Advances in targeting RAS
mutant cancers. Sci Signal
2020; 13.</Citation>
        </Reference>
        <Reference>
          <Citation>Boyd KP, Korf BR, Theos A. Neurofibromatosis type 1. J Am Acad Dermatol
2009; 61:
1–14; quiz
15–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2716546</ArticleId>
            <ArticleId IdType="pubmed">19539839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rad E, Tee AR. Neurofibromatosis type 1: Fundamental insights into cell
signalling and cancer. Semin Cell Dev Biol
2016; 52:
39–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26860753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ. Neurofibromatosis type 1. Nat Rev Dis Primers
2017; 3: 17004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28230061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferner RE. Neurofibromatosis 1 and neurofibromatosis 2: a twenty
first century perspective. Lancet Neurol
2007; 6:
340–351.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17362838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albers AC, Gutmann DH. Gliomas in patients with neurofibromatosis type
1. Expert Rev Neurother
2009; 9:
535–539.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19344304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fisher MJ, Loguidice M, Gutmann DH, Listernick R, Ferner RE, Ullrich NJ
et al.
Visual outcomes in children with neurofibromatosis type
1-associated optic pathway glioma following chemotherapy: a multicenter
retrospective analysis. Neuro Oncol
2012; 14:
790–797.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3367846</ArticleId>
            <ArticleId IdType="pubmed">22474213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenbaum T, Wimmer K. Neurofibromatosis type 1 (NF1) and associated
tumors. Klin Padiatr
2014; 226:
309–315.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25062113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muir D, Neubauer D, Lim IT, Yachnis AT, Wallace MR. Tumorigenic properties of neurofibromin-deficient
neurofibroma Schwann cells. Am J Pathol
2001; 158:
501–513.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1850316</ArticleId>
            <ArticleId IdType="pubmed">11159187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chamseddin BH, Le LQ. Management of cutaneous neurofibroma: current therapy
and future directions. Neurooncol Adv
2020; 2:
i107–i116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7317049</ArticleId>
            <ArticleId IdType="pubmed">32642736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Theos A, Korf BR, American College of P, American Physiological S. Pathophysiology of neurofibromatosis type
1. Ann Intern Med
2006; 144:
842–849.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16754926</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gross AM, Wolters PL, Dombi E, Baldwin A, Whitcomb P, Fisher MJ
et al.
Selumetinib in Children with Inoperable Plexiform
Neurofibromas. N Engl J Med
2020; 382:
1430–1442.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7305659</ArticleId>
            <ArticleId IdType="pubmed">32187457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Z, Liu C, Patel AJ, Liao CP, Wang Y, Le LQ. Cells of origin in the embryonic nerve roots for
NF1-associated plexiform neurofibroma. Cancer Cell
2014; 26:
695–706.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4254535</ArticleId>
            <ArticleId IdType="pubmed">25446898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dombi E, Baldwin A, Marcus LJ, Fisher MJ, Weiss B, Kim A
et al.
Activity of Selumetinib in Neurofibromatosis Type 1-Related
Plexiform Neurofibromas. N Engl J Med
2016; 375:
2550–2560.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5508592</ArticleId>
            <ArticleId IdType="pubmed">28029918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in
neurofibromatosis 1. J Med Genet
2002; 39:
311–314.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1735122</ArticleId>
            <ArticleId IdType="pubmed">12011145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fuchs B, Spinner RJ, Rock MG. Malignant peripheral nerve sheath tumors: an
update. J Surg Orthop Adv
2005; 14:
168–174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16442014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bates JE, Peterson CR, Dhakal S, Giampoli EJ, Constine LS. Malignant peripheral nerve sheath tumors (MPNST): a SEER
analysis of incidence across the age spectrum and therapeutic interventions
in the pediatric population. Pediatr Blood Cancer
2014; 61:
1955–1960.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25130403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim A, Stewart DR, Reilly KM, Viskochil D, Miettinen MM, Widemann BC. Malignant Peripheral Nerve Sheath Tumors State of the
Science: Leveraging Clinical and Biological Insights into Effective
Therapies. Sarcoma
2017; 2017:
7429697.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5448069</ArticleId>
            <ArticleId IdType="pubmed">28592921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farid M, Demicco EG, Garcia R, Ahn L, Merola PR, Cioffi A
et al.
Malignant peripheral nerve sheath tumors.
Oncologist
2014; 19:
193–201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3926794</ArticleId>
            <ArticleId IdType="pubmed">24470531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>LaFemina J, Qin LX, Moraco NH, Antonescu CR, Fields RC, Crago AM
et al.
Oncologic outcomes of sporadic, neurofibromatosis-associated, and
radiation-induced malignant peripheral nerve sheath tumors.
Ann Surg Oncol
2013; 20:
66–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3567771</ArticleId>
            <ArticleId IdType="pubmed">22878618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pekmezci M, Reuss DE, Hirbe AC, Dahiya S, Gutmann DH, von Deimling A
et al.
Morphologic and immunohistochemical features of malignant
peripheral nerve sheath tumors and cellular schwannomas.
Mod Pathol
2015; 28:
187–200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6816504</ArticleId>
            <ArticleId IdType="pubmed">25189642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miettinen MM, Antonescu CR, Fletcher CDM, Kim A, Lazar AJ, Quezado MM
et al.
Histopathologic evaluation of atypical neurofibromatous tumors
and their transformation into malignant peripheral nerve sheath tumor in
patients with neurofibromatosis 1-a consensus overview.
Hum Pathol
2017; 67:
1–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5628119</ArticleId>
            <ArticleId IdType="pubmed">28551330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Longo JF, Weber SM, Turner-Ivey BP, Carroll SL. Recent Advances in the Diagnosis and Pathogenesis of
Neurofibromatosis Type 1 (NF1)-associated Peripheral Nervous System
Neoplasms. Adv Anat Pathol
2018; 25:
353–368.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29762158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brosseau JP, Liao CP, Wang Y, Ramani V, Vandergriff T, Lee M
et al.
NF1 heterozygosity fosters de novo tumorigenesis but impairs
malignant transformation. Nat Commun
2018; 9: 5014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6258697</ArticleId>
            <ArticleId IdType="pubmed">30479396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kolberg M, Holand M, Agesen TH, Brekke HR, Liestol K, Hall KS
et al.
Survival meta-analyses for &gt;1800 malignant peripheral
nerve sheath tumor patients with and without neurofibromatosis type
1. Neuro Oncol
2013; 15:
135–147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3548581</ArticleId>
            <ArticleId IdType="pubmed">23161774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bottillo I, Ahlquist T, Brekke H, Danielsen SA, van den Berg E, Mertens F
et al.
Germline and somatic NF1 mutations in sporadic and NF1-associated
malignant peripheral nerve sheath tumours. J Pathol
2009; 217:
693–701.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19142971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pemov A, Li H, Presley W, Wallace MR, Miller DT. Genetics of human malignant peripheral nerve sheath
tumors. Neurooncol Adv
2020; 2:
i50–i61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7317054</ArticleId>
            <ArticleId IdType="pubmed">32642732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ebben JD, Treisman DM, Zorniak M, Kutty RG, Clark PA, Kuo JS. The cancer stem cell paradigm: a new understanding of
tumor development and treatment. Expert Opin Ther Targets
2010; 14:
621–632.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3657606</ArticleId>
            <ArticleId IdType="pubmed">20426697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J
et al.
A cell initiating human acute myeloid leukaemia after
transplantation into SCID mice. Nature
1994; 367:
645–648.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7509044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer
cells. Proc Natl Acad Sci U S A
2003; 100:
3983–3988.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC153034</ArticleId>
            <ArticleId IdType="pubmed">12629218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J
et al.
Identification of a cancer stem cell in human brain
tumors. Cancer Res
2003; 63:
5821–5828.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14522905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I, Vogel S
et al.
Identification of bronchioalveolar stem cells in normal lung and
lung cancer. Cell
2005; 121:
823–835.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15960971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spyra M, Kluwe L, Hagel C, Nguyen R, Panse J, Kurtz A
et al.
Cancer stem cell-like cells derived from malignant peripheral
nerve sheath tumors. PLoS One
2011; 6: e21099.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3113907</ArticleId>
            <ArticleId IdType="pubmed">21695156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun D, Xie XP, Zhang X, Wang Z, Sait SF, Iyer SV
et al.
Stem-like cells drive NF1-associated MPNST functional
heterogeneity and tumor progression. Cell Stem Cell
2021; 28: 1397–1410
e1394.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8349880</ArticleId>
            <ArticleId IdType="pubmed">34010628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laycock-van Spyk S, Thomas N, Cooper DN, Upadhyaya M. Neurofibromatosis type 1-associated tumours: their
somatic mutational spectrum and pathogenesis. Hum Genomics
2011; 5:
623–690.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3525246</ArticleId>
            <ArticleId IdType="pubmed">22155606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brohl AS, Kahen E, Yoder SJ, Teer JK, Reed DR. The genomic landscape of malignant peripheral nerve
sheath tumors: diverse drivers of Ras pathway activation.
Sci Rep
2017; 7: 14992.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5678116</ArticleId>
            <ArticleId IdType="pubmed">29118384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lemberg KM, Wang J, Pratilas CA. From Genes to -Omics: The Evolving Molecular Landscape
of Malignant Peripheral Nerve Sheath Tumor. Genes (Basel)
2020; 11.</Citation>
        </Reference>
        <Reference>
          <Citation>Kaplan HG, Rostad S, Ross JS, Ali SM, Millis SZ. Genomic Profiling in Patients With Malignant Peripheral
Nerve Sheath Tumors Reveals Multiple Pathways With Targetable
Mutations. J Natl Compr Canc Netw
2018; 16:
967–974.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30099373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beert E, Brems H, Daniels B, De Wever I, Van Calenbergh F, Schoenaers J
et al.
Atypical neurofibromas in neurofibromatosis type 1 are
premalignant tumors. Genes Chromosomes Cancer
2011; 50:
1021–1032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21987445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaney KE, Perrino MR, Kershner LJ, Patel AV, Wu J, Choi K
et al.
Cdkn2a Loss in a Model of Neurofibroma Demonstrates Stepwise
Tumor Progression to Atypical Neurofibroma and MPNST.
Cancer Res
2020; 80:
4720–4730.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7968129</ArticleId>
            <ArticleId IdType="pubmed">32816910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Legius E, Dierick H, Wu R, Hall BK, Marynen P, Cassiman JJ
et al.
TP53 mutations are frequent in malignant NF1
tumors. Genes Chromosomes Cancer
1994; 10:
250–255.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7522538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verdijk RM, den Bakker MA, Dubbink HJ, Hop WC, Dinjens WN, Kros JM. TP53 mutation analysis of malignant peripheral nerve
sheath tumors. J Neuropathol Exp Neurol
2010; 69:
16–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20010306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jouhilahti EM, Peltonen S, Heape AM, Peltonen J. The pathoetiology of neurofibromatosis
1. Am J Pathol
2011; 178:
1932–1939.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3081157</ArticleId>
            <ArticleId IdType="pubmed">21457932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carroll SL. Molecular mechanisms promoting the pathogenesis of
Schwann cell neoplasms. Acta Neuropathol
2012; 123:
321–348.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3288530</ArticleId>
            <ArticleId IdType="pubmed">22160322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carroll SL. The Challenge of Cancer Genomics in Rare Nervous System
Neoplasms: Malignant Peripheral Nerve Sheath Tumors as a Paradigm for
Cross-Species Comparative Oncogenomics. Am J Pathol
2016; 186:
464–477.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4816695</ArticleId>
            <ArticleId IdType="pubmed">26740486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mertens F, Rydholm A, Bauer HF, Limon J, Nedoszytko B, Szadowska A
et al.
Cytogenetic findings in malignant peripheral nerve sheath
tumors. Int J Cancer
1995; 61:
793–798.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7790113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berner JM, Sorlie T, Mertens F, Henriksen J, Saeter G, Mandahl N
et al.
Chromosome band 9p21 is frequently altered in malignant
peripheral nerve sheath tumors: studies of CDKN2A and other genes of the pRB
pathway. Genes Chromosomes Cancer
1999; 26:
151–160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10469453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmidt H, Taubert H, Wurl P, Bache M, Bartel F, Holzhausen HJ
et al.
Cytogenetic characterization of six malignant peripheral nerve
sheath tumors: comparison of karyotyping and comparative genomic
hybridization. Cancer Genet Cytogenet
2001; 128:
14–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11454424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dehner C, Moon CI, Zhang X, Zhou Z, Miller C, Xu H
et al.
Chromosome 8 gain is associated with high-grade transformation in
MPNST. JCI Insight
2021; 6.</Citation>
        </Reference>
        <Reference>
          <Citation>Peacock JD, Pridgeon MG, Tovar EA, Essenburg CJ, Bowman M, Madaj Z
et al.
Genomic Status of MET Potentiates Sensitivity to MET and MEK
Inhibition in NF1-Related Malignant Peripheral Nerve Sheath
Tumors. Cancer Res
2018; 78:
3672–3687.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6235171</ArticleId>
            <ArticleId IdType="pubmed">29720369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pemov A, Hansen NF, Sindiri S, Patidar R, Higham CS, Dombi E
et al.
Low mutation burden and frequent loss of CDKN2A/B and SMARCA2,
but not PRC2, define premalignant neurofibromatosis type 1-associated
atypical neurofibromas. Neuro Oncol
2019; 21:
981–992.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6682216</ArticleId>
            <ArticleId IdType="pubmed">30722027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Szymanski JJ, Sundby RT, Jones PA, Srihari D, Earland N, Harris PK
et al.
Cell-free DNA ultra-low-pass whole genome sequencing to
distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign
precursor lesion: A cross-sectional study. PLoS Med
2021; 18:
e1003734.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8407545</ArticleId>
            <ArticleId IdType="pubmed">34464388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holtkamp N, Malzer E, Zietsch J, Okuducu AF, Mucha J, Mawrin C
et al.
EGFR and erbB2 in malignant peripheral nerve sheath tumors and
implications for targeted therapy. Neuro Oncol
2008; 10:
946–957.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2719009</ArticleId>
            <ArticleId IdType="pubmed">18650488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holtkamp N, Okuducu AF, Mucha J, Afanasieva A, Hartmann C, Atallah I
et al.
Mutation and expression of PDGFRA and KIT in malignant peripheral
nerve sheath tumors, and its implications for imatinib
sensitivity. Carcinogenesis
2006; 27:
664–671.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16357008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mantripragada KK, Spurlock G, Kluwe L, Chuzhanova N, Ferner RE, Frayling IM
et al.
High-resolution DNA copy number profiling of malignant peripheral
nerve sheath tumors using targeted microarray-based comparative genomic
hybridization. Clin Cancer Res
2008; 14:
1015–1024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18281533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patwardhan PP, Surriga O, Beckman MJ, de Stanchina E, Dematteo RP, Tap WD
et al.
Sustained inhibition of receptor tyrosine kinases and macrophage
depletion by PLX3397 and rapamycin as a potential new approach for the
treatment of MPNSTs. Clin Cancer Res
2014; 20:
3146–3158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4060793</ArticleId>
            <ArticleId IdType="pubmed">24718867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ki DH, He S, Rodig S, Look AT. Overexpression of PDGFRA cooperates with loss of NF1 and
p53 to accelerate the molecular pathogenesis of malignant peripheral nerve
sheath tumors. Oncogene
2017; 36:
1058–1068.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5332555</ArticleId>
            <ArticleId IdType="pubmed">27477693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J, Patmore DM, Jousma E, Eaves DW, Breving K, Patel AV
et al.
EGFR-STAT3 signaling promotes formation of malignant peripheral
nerve sheath tumors. Oncogene
2014; 33:
173–180.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3923530</ArticleId>
            <ArticleId IdType="pubmed">23318430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang J, Ylipaa A, Sun Y, Zheng H, Chen K, Nykter M
et al.
Genomic and molecular characterization of malignant peripheral
nerve sheath tumor identifies the IGF1R pathway as a primary target for
treatment. Clin Cancer Res
2011; 17:
7563–7573.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3243813</ArticleId>
            <ArticleId IdType="pubmed">22042973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J
et al.
The landscape of somatic copy-number alteration across human
cancers. Nature
2010; 463:
899–905.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2826709</ArticleId>
            <ArticleId IdType="pubmed">20164920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chau V, Lim SK, Mo W, Liu C, Patel AJ, McKay RM
et al.
Preclinical therapeutic efficacy of a novel pharmacologic inducer
of apoptosis in malignant peripheral nerve sheath tumors.
Cancer Res
2014; 74:
586–597.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3947005</ArticleId>
            <ArticleId IdType="pubmed">24285727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel AJ, Liao CP, Chen Z, Liu C, Wang Y, Le LQ. BET bromodomain inhibition triggers apoptosis of
NF1-associated malignant peripheral nerve sheath tumors through Bim
induction. Cell Rep
2014; 6:
81–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3904298</ArticleId>
            <ArticleId IdType="pubmed">24373973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Raedt T, Beert E, Pasmant E, Luscan A, Brems H, Ortonne N
et al.
PRC2 loss amplifies Ras-driven transcription and confers
sensitivity to BRD4-based therapies. Nature
2014; 514:
247–251.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25119042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee W, Teckie S, Wiesner T, Ran L, Prieto Granada CN, Lin M
et al.
PRC2 is recurrently inactivated through EED or SUZ12 loss in
malignant peripheral nerve sheath tumors. Nat Genet
2014; 46:
1227–1232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4249650</ArticleId>
            <ArticleId IdType="pubmed">25240281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang M, Wang Y, Jones S, Sausen M, McMahon K, Sharma R
et al.
Somatic mutations of SUZ12 in malignant peripheral nerve sheath
tumors. Nat Genet
2014; 46:
1170–1172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4383254</ArticleId>
            <ArticleId IdType="pubmed">25305755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morey L, Helin K. Polycomb group protein-mediated repression of
transcription. Trends Biochem Sci
2010; 35:
323–332.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20346678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harachi M, Masui K, Cavenee WK, Mischel PS, Shibata N. Protein Acetylation at the Interface of Genetics,
Epigenetics and Environment in Cancer.
Metabolites
2021; 11.</Citation>
        </Reference>
        <Reference>
          <Citation>Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S
et al.
Mutations of the BRAF gene in human cancer.
Nature
2002; 417:
949–954.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12068308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirbe AC, Pekmezci M, Dahiya S, Apicelli AJ, Van Tine BA, Perry A
et al.
BRAFV600E mutation in sporadic and neurofibromatosis type
1-related malignant peripheral nerve sheath tumors.
Neuro Oncol
2014; 16:
466–467.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3922521</ArticleId>
            <ArticleId IdType="pubmed">24366910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Longo JF, Brosius SN, Znoyko I, Alers VA, Jenkins DP, Wilson RC
et al.
Establishment and genomic characterization of a sporadic
malignant peripheral nerve sheath tumor cell line.
Sci Rep
2021; 11: 5690.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7952412</ArticleId>
            <ArticleId IdType="pubmed">33707600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller DT, Cortes-Ciriano I, Pillay N, Hirbe AC, Snuderl M, Bui MM
et al.
Genomics of MPNST (GeM) Consortium: Rationale and Study Design
for Multi-Omic Characterization of NF1-Associated and Sporadic
MPNSTs. Genes (Basel)
2020; 11.</Citation>
        </Reference>
        <Reference>
          <Citation>Badache A, De Vries GH. Neurofibrosarcoma-derived Schwann cells overexpress
platelet-derived growth factor (PDGF) receptors and are induced to
proliferate by PDGF BB. J Cell Physiol
1998; 177:
334–342.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9766530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller SJ, Rangwala F, Williams J, Ackerman P, Kong S, Jegga AG
et al.
Large-scale molecular comparison of human schwann cells to
malignant peripheral nerve sheath tumor cell lines and
tissues. Cancer Res
2006; 66:
2584–2591.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16510576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun D, Tainsky MA, Haddad R. Oncogene Mutation Survey in MPNST Cell Lines Enhances
the Dominant Role of Hyperactive Ras in NF1 Associated Pro-Survival and
Malignancy. Transl Oncogenomics
2012; 5:
1–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3273949</ArticleId>
            <ArticleId IdType="pubmed">22346343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo J, Grovola MR, Xie H, Coggins GE, Duggan P, Hasan R
et al.
Comprehensive pharmacological profiling of neurofibromatosis cell
lines. Am J Cancer Res
2017; 7:
923–934.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5411799</ArticleId>
            <ArticleId IdType="pubmed">28469964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kolberg M, Bruun J, Murumagi A, Mpindi JP, Bergsland CH, Holand M
et al.
Drug sensitivity and resistance testing identifies PLK1
inhibitors and gemcitabine as potent drugs for malignant peripheral nerve
sheath tumors. Mol Oncol
2017; 11:
1156–1171.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5579334</ArticleId>
            <ArticleId IdType="pubmed">28556483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fang Y, Elahi A, Denley RC, Rao PH, Brennan MF, Jhanwar SC. Molecular characterization of permanent cell lines from
primary, metastatic and recurrent malignant peripheral nerve sheath tumors
(MPNST) with underlying neurofibromatosis-1.
Anticancer Res
2009; 29:
1255–1262.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19414372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jia LQ, Osada M, Ishioka C, Gamo M, Ikawa S, Suzuki T
et al.
Screening the p53 status of human cell lines using a yeast
functional assay. Mol Carcinog
1997; 19:
243–253.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9290701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeClue JE, Papageorge AG, Fletcher JA, Diehl SR, Ratner N, Vass WC
et al.
Abnormal regulation of mammalian p21ras contributes to malignant
tumor growth in von Recklinghausen (type 1)
neurofibromatosis. Cell
1992; 69:
265–273.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1568246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ryan JJ, Klein KA, Neuberger TJ, Leftwich JA, Westin EH, Kauma S
et al.
Role for the stem cell factor/KIT complex in Schwann cell
neoplasia and mast cell proliferation associated with
neurofibromatosis. J Neurosci Res
1994; 37:
415–432.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7513766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeClue JE, Heffelfinger S, Benvenuto G, Ling B, Li S, Rui W
et al.
Epidermal growth factor receptor expression in neurofibromatosis
type 1-related tumors and NF1 animal models. J Clin Invest
2000; 105:
1233–1241.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC315438</ArticleId>
            <ArticleId IdType="pubmed">10791998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hakozaki M, Hojo H, Sato M, Tajino T, Yamada H, Kikuchi S
et al.
Establishment and characterization of a novel human malignant
peripheral nerve sheath tumor cell line, FMS-1, that overexpresses epidermal
growth factor receptor and cyclooxygenase-2.
Virchows Arch
2009; 455:
517–526.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19921253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dang I, DeVries GH. Schwann cell lines derived from malignant peripheral
nerve sheath tumors respond abnormally to platelet-derived growth
factor-BB. J Neurosci Res
2005; 79:
318–328.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15602756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Torres KE, Zhu QS, Bill K, Lopez G, Ghadimi MP, Xie X
et al.
Activated MET is a molecular prognosticator and potential
therapeutic target for malignant peripheral nerve sheath
tumors. Clin Cancer Res
2011; 17:
3943–3955.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3117912</ArticleId>
            <ArticleId IdType="pubmed">21540237</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eckert JM, Byer SJ, Clodfelder-Miller BJ, Carroll SL. Neuregulin-1 beta and neuregulin-1 alpha differentially
affect the migration and invasion of malignant peripheral nerve sheath tumor
cells. Glia
2009; 57:
1501–1520.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2744852</ArticleId>
            <ArticleId IdType="pubmed">19306381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Demestre M, Terzi MY, Mautner V, Vajkoczy P, Kurtz A, Pina AL. Effects of pigment epithelium derived factor (PEDF) on
malignant peripheral nerve sheath tumours (MPNSTs).
J Neurooncol
2013; 115:
391–399.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24078214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perrin GQ, Li H, Fishbein L, Thomson SA, Hwang MS, Scarborough MT
et al.
An orthotopic xenograft model of intraneural NF1 MPNST suggests a
potential association between steroid hormones and tumor cell
proliferation. Lab Invest
2007; 87:
1092–1102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17876295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byer SJ, Eckert JM, Brossier NM, Clodfelder-Miller BJ, Turk AN, Carroll AJ
et al.
Tamoxifen inhibits malignant peripheral nerve sheath tumor growth
in an estrogen receptor-independent manner. Neuro Oncol
2011; 13:
28–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3018903</ArticleId>
            <ArticleId IdType="pubmed">21075781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imaizumi S, Motoyama T, Ogose A, Hotta T, Takahashi HE. Characterization and chemosensitivity of two human
malignant peripheral nerve sheath tumour cell lines derived from a patient
with neurofibromatosis type 1. Virchows Arch
1998; 433:
435–441.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9849858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirokawa Y, Nakajima H, Hanemann CO, Kurtz A, Frahm S, Mautner V
et al.
Signal therapy of NF1-deficient tumor xenograft in mice by the
anti-PAK1 drug FK228. Cancer Biol Ther
2005; 4:
379–381.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15846074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohishi J, Aoki M, Nabeshima K, Suzumiya J, Takeuchi T, Ogose A
et al.
Imatinib mesylate inhibits cell growth of malignant peripheral
nerve sheath tumors in vitro and in vivo through suppression of
PDGFR-beta. BMC Cancer
2013; 13: 224.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3654969</ArticleId>
            <ArticleId IdType="pubmed">23642185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W, Lin W, Hong B, Li X, Zhang M, Zhang L
et al.
Effect of triptolide on malignant peripheral nerve sheath tumours
in vitro and in vivo. J Int Med Res
2012; 40:
2284–2294.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23321185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deyle DR, Escobar DZ, Peng KW, Babovic-Vuksanovic D. Oncolytic measles virus as a novel therapy for malignant
peripheral nerve sheath tumors. Gene
2015; 565:
140–145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25843626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maldonado AR, Klanke C, Jegga AG, Aronow BJ, Mahller YY, Cripe TP
et al.
Molecular engineering and validation of an oncolytic herpes
simplex virus type 1 transcriptionally targeted to midkine-positive
tumors. J Gene Med
2010; 12:
613–623.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20603890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rahrmann EP, Watson AL, Keng VW, Choi K, Moriarity BS, Beckmann DA
et al.
Forward genetic screen for malignant peripheral nerve sheath
tumor formation identifies new genes and pathways driving
tumorigenesis. Nat Genet
2013; 45:
756–766.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3695033</ArticleId>
            <ArticleId IdType="pubmed">23685747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watson AL, Rahrmann EP, Moriarity BS, Choi K, Conboy CB, Greeley AD
et al.
Canonical Wnt/beta-catenin signaling drives human schwann cell
transformation, progression, and tumor maintenance.
Cancer Discov
2013; 3:
674–689.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3679355</ArticleId>
            <ArticleId IdType="pubmed">23535903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li H, Chang LJ, Neubauer DR, Muir DF, Wallace MR. Immortalization of human normal and NF1 neurofibroma
Schwann cells. Lab Invest
2016; 96:
1105–1115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27617404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kraniak JM, Chalasani A, Wallace MR, Mattingly RR. Development of 3D culture models of plexiform
neurofibroma and initial application for phenotypic characterization and
drug screening. Exp Neurol
2018; 299:
289–298.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6863155</ArticleId>
            <ArticleId IdType="pubmed">29055717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moll C, Reboredo J, Schwarz T, Appelt A, Schurlein S, Walles H
et al.
Tissue engineering of a human 3D in vitro tumor test
system. J Vis Exp
2013.</Citation>
        </Reference>
        <Reference>
          <Citation>The I, Hannigan GE, Cowley GS, Reginald S, Zhong Y, Gusella JF
et al.
Rescue of a Drosophila NF1 mutant phenotype by protein kinase
A. Science
1997; 276:
791–794.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9115203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo HF, Tong J, Hannan F, Luo L, Zhong Y. A neurofibromatosis-1-regulated pathway is required for
learning in Drosophila. Nature
2000; 403:
895–898.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10706287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ho IS, Hannan F, Guo HF, Hakker I, Zhong Y. Distinct functional domains of neurofibromatosis type 1
regulate immediate versus long-term memory formation.
J Neurosci
2007; 27:
6852–6857.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6672704</ArticleId>
            <ArticleId IdType="pubmed">17581973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buchanan ME, Davis RL. A distinct set of Drosophila brain neurons required for
neurofibromatosis type 1-dependent learning and memory.
J Neurosci
2010; 30:
10135–10143.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2917756</ArticleId>
            <ArticleId IdType="pubmed">20668197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gouzi JY, Moressis A, Walker JA, Apostolopoulou AA, Palmer RH, Bernards A
et al.
The receptor tyrosine kinase Alk controls neurofibromin functions
in Drosophila growth and learning. PLoS Genet
2011; 7: e1002281.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3174217</ArticleId>
            <ArticleId IdType="pubmed">21949657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van der Voet M, Harich B, Franke B, Schenck A. ADHD-associated dopamine transporter, latrophilin and
neurofibromin share a dopamine-related locomotor signature in
Drosophila. Mol Psychiatry
2016; 21:
565–573.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4804182</ArticleId>
            <ArticleId IdType="pubmed">25962619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>King LB, Koch M, Murphy KR, Velazquez Y, Ja WW, Tomchik SM. Neurofibromin Loss of Function Drives Excessive Grooming
in Drosophila. G3 (Bethesda)
2016; 6:
1083–1093.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4825643</ArticleId>
            <ArticleId IdType="pubmed">26896440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walker JA, Gouzi JY, Long JB, Huang S, Maher RC, Xia H
et al.
Genetic and functional studies implicate synaptic overgrowth and
ring gland cAMP/PKA signaling defects in the Drosophila melanogaster
neurofibromatosis-1 growth deficiency. PLoS Genet
2013; 9: e1003958.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3836801</ArticleId>
            <ArticleId IdType="pubmed">24278035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo HF, The I, Hannan F, Bernards A, Zhong Y. Requirement of Drosophila NF1 for activation of adenylyl
cyclase by PACAP38-like neuropeptides.
Science
1997; 276:
795–798.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9115204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Williams JA, Su HS, Bernards A, Field J, Sehgal A. A circadian output in Drosophila mediated by
neurofibromatosis-1 and Ras/MAPK. Science
2001; 293:
2251–2256.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11567138</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>King LB, Boto T, Botero V, Aviles AM, Jomsky BM, Joseph C
et al.
Developmental loss of neurofibromin across distributed neuronal
circuits drives excessive grooming in Drosophila.
PLoS Genet
2020; 16:
e1008920.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7398555</ArticleId>
            <ArticleId IdType="pubmed">32697780</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tong J, Hannan F, Zhu Y, Bernards A, Zhong Y. Neurofibromin regulates G protein-stimulated adenylyl
cyclase activity. Nat Neurosci
2002; 5:
95–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11788835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>MacInnes AW, Amsterdam A, Whittaker CA, Hopkins N, Lees JA. Loss of p53 synthesis in zebrafish tumors with ribosomal
protein gene mutations. Proc Natl Acad Sci U S A
2008; 105:
10408–10413.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2492501</ArticleId>
            <ArticleId IdType="pubmed">18641120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shin J, Padmanabhan A, de Groh ED, Lee JS, Haidar S, Dahlberg S
et al.
Zebrafish neurofibromatosis type 1 genes have redundant functions
in tumorigenesis and embryonic development. Dis Model Mech
2012; 5:
881–894.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3484870</ArticleId>
            <ArticleId IdType="pubmed">22773753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ki DH, Oppel F, Durbin AD, Look AT. Mechanisms underlying synergy between DNA topoisomerase
I-targeted drugs and mTOR kinase inhibitors in NF1-associated malignant
peripheral nerve sheath tumors. Oncogene
2019; 38:
6585–6598.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31444410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oppel F, Tao T, Shi H, Ross KN, Zimmerman MW, He S
et al.
Loss of atrx cooperates with p53-deficiency to promote the
development of sarcomas and other malignancies. PLoS Genet
2019; 15:
e1008039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6476535</ArticleId>
            <ArticleId IdType="pubmed">30970016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Astone M, Pizzi M, Peron M, Domenichini A, Guzzardo V, Tochterle S
et al.
A GFP-Tagged Gross Deletion on Chromosome 1 Causes Malignant
Peripheral Nerve Sheath Tumors and Carcinomas in Zebrafish.
PLoS One
2015; 10:
e0145178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4687860</ArticleId>
            <ArticleId IdType="pubmed">26695815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumari R, Silic MR, Jones-Hall YL, Nin-Velez A, Yang JY, Mittal SK
et al.
Identification of RECK as an evolutionarily conserved tumor
suppressor gene for zebrafish malignant peripheral nerve sheath
tumors. Oncotarget
2018; 9:
23494–23504.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5955097</ArticleId>
            <ArticleId IdType="pubmed">29805750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reilly KM, Kim A, Blakely J, Ferner RE, Gutmann DH, Legius E
et al.
Neurofibromatosis Type 1-Associated MPNST State of the Science:
Outlining a Research Agenda for the Future. J Natl Cancer Inst
2017; 109.</Citation>
        </Reference>
        <Reference>
          <Citation>Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A, Weinberg RA. Tumour predisposition in mice heterozygous for a
targeted mutation in Nf1. Nat Genet
1994; 7:
353–361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7920653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brannan CI, Perkins AS, Vogel KS, Ratner N, Nordlund ML, Reid SW
et al.
Targeted disruption of the neurofibromatosis type-1 gene leads to
developmental abnormalities in heart and various neural crest-derived
tissues. Genes Dev
1994; 8:
1019–1029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7926784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joseph NM, Mosher JT, Buchstaller J, Snider P, McKeever PE, Lim M
et al.
The loss of Nf1 transiently promotes self-renewal but not
tumorigenesis by neural crest stem cells. Cancer Cell
2008; 13:
129–140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2566828</ArticleId>
            <ArticleId IdType="pubmed">18242513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to
cancer etiology and molecular pathogenesis. Cancer Res
1994; 54:
4855–4878.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8069852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vogel KS, Klesse LJ, Velasco-Miguel S, Meyers K, Rushing EJ, Parada LF. Mouse tumor model for neurofibromatosis type
1. Science
1999; 286:
2176–2179.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3079436</ArticleId>
            <ArticleId IdType="pubmed">10591653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cichowski K, Shih TS, Schmitt E, Santiago S, Reilly K, McLaughlin ME
et al.
Mouse models of tumor development in neurofibromatosis type
1. Science
1999; 286:
2172–2176.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10591652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reilly KM, Tuskan RG, Christy E, Loisel DA, Ledger J, Bronson RT
et al.
Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is
linked to chromosome 11 and subject to epigenetic effects.
Proc Natl Acad Sci U S A
2004; 101:
13008–13013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC516509</ArticleId>
            <ArticleId IdType="pubmed">15319471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johannessen CM, Johnson BW, Williams SM, Chan AW, Reczek EE, Lynch RC
et al.
TORC1 is essential for NF1-associated
malignancies. Curr Biol
2008; 18:
56–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18164202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malone CF, Fromm JA, Maertens O, DeRaedt T, Ingraham R, Cichowski K. Defining key signaling nodes and therapeutic biomarkers
in NF1-mutant cancers. Cancer Discov
2014; 4:
1062–1073.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4446704</ArticleId>
            <ArticleId IdType="pubmed">24913553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lock R, Ingraham R, Maertens O, Miller AL, Weledji N, Legius E
et al.
Cotargeting MNK and MEK kinases induces the regression of
NF1-mutant cancers. J Clin Invest
2016; 126:
2181–2190.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4887164</ArticleId>
            <ArticleId IdType="pubmed">27159396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Raedt T, Walton Z, Yecies JL, Li D, Chen Y, Malone CF
et al.
Exploiting cancer cell vulnerabilities to develop a combination
therapy for ras-driven tumors. Cancer Cell
2011; 20:
400–413.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3233475</ArticleId>
            <ArticleId IdType="pubmed">21907929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mo W, Chen J, Patel A, Zhang L, Chau V, Li Y
et al.
CXCR4/CXCL12 mediate autocrine cell- cycle progression in
NF1-associated malignant peripheral nerve sheath tumors.
Cell
2013; 152:
1077–1090.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3594500</ArticleId>
            <ArticleId IdType="pubmed">23434321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huijbregts RP, Roth KA, Schmidt RE, Carroll SL. Hypertrophic neuropathies and malignant peripheral nerve
sheath tumors in transgenic mice overexpressing glial growth factor beta3 in
myelinating Schwann cells. J Neurosci
2003; 23:
7269–7280.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6740435</ArticleId>
            <ArticleId IdType="pubmed">12917360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kazmi SJ, Byer SJ, Eckert JM, Turk AN, Huijbregts RP, Brossier NM
et al.
Transgenic mice overexpressing neuregulin-1 model
neurofibroma-malignant peripheral nerve sheath tumor progression and
implicate specific chromosomal copy number variations in
tumorigenesis. Am J Pathol
2013; 182:
646–667.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3586689</ArticleId>
            <ArticleId IdType="pubmed">23321323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keng VW, Rahrmann EP, Watson AL, Tschida BR, Moertel CL, Jessen WJ
et al.
PTEN and NF1 inactivation in Schwann cells produces a severe
phenotype in the peripheral nervous system that promotes the development and
malignant progression of peripheral nerve sheath tumors.
Cancer Res
2012; 72:
3405–3413.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3428071</ArticleId>
            <ArticleId IdType="pubmed">22700876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rhodes SD, He Y, Smith A, Jiang L, Lu Q, Mund J
et al.
Cdkn2a (Arf) loss drives NF1-associated atypical neurofibroma and
malignant transformation. Hum Mol Genet
2019; 28:
2752–2762.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6687955</ArticleId>
            <ArticleId IdType="pubmed">31091306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gregorian C, Nakashima J, Dry SM, Nghiemphu PL, Smith KB, Ao Y
et al.
PTEN dosage is essential for neurofibroma development and
malignant transformation. Proc Natl Acad Sci U S A
2009; 106:
19479–19484.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2765459</ArticleId>
            <ArticleId IdType="pubmed">19846776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keng VW, Watson AL, Rahrmann EP, Li H, Tschida BR, Moriarity BS
et al.
Conditional Inactivation of Pten with EGFR Overexpression in
Schwann Cells Models Sporadic MPNST.
Sarcoma
2012; 2012:
620834.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3539440</ArticleId>
            <ArticleId IdType="pubmed">23319880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rahrmann EP, Moriarity BS, Otto GM, Watson AL, Choi K, Collins MH
et al.
Trp53 haploinsufficiency modifies EGFR-driven peripheral nerve
sheath tumorigenesis. Am J Pathol
2014; 184:
2082–2098.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4076465</ArticleId>
            <ArticleId IdType="pubmed">24832557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dodd RD, Mito JK, Eward WC, Chitalia R, Sachdeva M, Ma Y
et al.
NF1 deletion generates multiple subtypes of soft-tissue sarcoma
that respond to MEK inhibition. Mol Cancer Ther
2013; 12:
1906–1917.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3825462</ArticleId>
            <ArticleId IdType="pubmed">23858101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dodd RD, Lee CL, Overton T, Huang W, Eward WC, Luo L
et al.
NF1(+/−) Hematopoietic Cells Accelerate Malignant
Peripheral Nerve Sheath Tumor Development without Altering Chemotherapy
Response. Cancer Res
2017; 77:
4486–4497.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5839126</ArticleId>
            <ArticleId IdType="pubmed">28646022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang J, Chen M, Whitley MJ, Kuo HC, Xu ES, Walens A
et al.
Generation and comparison of CRISPR-Cas9 and Cre-mediated
genetically engineered mouse models of sarcoma. Nat Commun
2017; 8: 15999.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5508130</ArticleId>
            <ArticleId IdType="pubmed">28691711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirbe AC, Dahiya S, Friedmann-Morvinski D, Verma IM, Clapp DW, Gutmann DH. Spatially- and temporally-controlled postnatal p53
knockdown cooperates with embryonic Schwann cell precursor Nf1 gene loss to
promote malignant peripheral nerve sheath tumor formation.
Oncotarget
2016; 7:
7403–7414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4884927</ArticleId>
            <ArticleId IdType="pubmed">26859681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mak IW, Evaniew N, Ghert M. Lost in translation: animal models and clinical trials
in cancer treatment. Am J Transl Res
2014; 6:
114–118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3902221</ArticleId>
            <ArticleId IdType="pubmed">24489990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhola P, Banerjee S, Mukherjee J, Balasubramanium A, Arun V, Karim Z
et al.
Preclinical in vivo evaluation of rapamycin in human malignant
peripheral nerve sheath explant xenograft. Int J Cancer
2010; 126:
563–571.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19634141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takamiya Y, Friedlander RM, Brem H, Malick A, Martuza RL. Inhibition of angiogenesis and growth of human
nerve-sheath tumors by AGM-1470. J Neurosurg
1993; 78:
470–476.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8433151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castellsague J, Gel B, Fernandez-Rodriguez J, Llatjos R, Blanco I, Benavente Y
et al.
Comprehensive establishment and characterization of
orthoxenograft mouse models of malignant peripheral nerve sheath tumors for
personalized medicine. EMBO Mol Med
2015; 7:
608–627.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4492820</ArticleId>
            <ArticleId IdType="pubmed">25810463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pollard K, Banerjee J, Doan X, Wang J, Guo X, Allaway R
et al.
A clinically and genomically annotated nerve sheath tumor
biospecimen repository. Sci Data
2020; 7: 184.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7305302</ArticleId>
            <ArticleId IdType="pubmed">32561749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inoue A, Deem AK, Kopetz S, Heffernan TP, Draetta GF, Carugo A. Current and Future Horizons of Patient-Derived Xenograft
Models in Colorectal Cancer Translational Research.
Cancers (Basel)
2019; 11.</Citation>
        </Reference>
        <Reference>
          <Citation>Yoshida GJ. Applications of patient-derived tumor xenograft models
and tumor organoids. J Hematol Oncol
2020; 13: 4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6947974</ArticleId>
            <ArticleId IdType="pubmed">31910904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic
and adult fibroblast cultures by defined factors.
Cell
2006; 126:
663–676.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16904174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K
et al.
Induction of pluripotent stem cells from adult human fibroblasts
by defined factors. Cell
2007; 131:
861–872.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18035408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carrio M, Mazuelas H, Richaud-Patin Y, Gel B, Terribas E, Rosas I
et al.
Reprogramming Captures the Genetic and Tumorigenic Properties of
Neurofibromatosis Type 1 Plexiform Neurofibromas.
Stem Cell Reports
2019; 12:
411–426.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6373434</ArticleId>
            <ArticleId IdType="pubmed">30713041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anastasaki C, Wegscheid ML, Hartigan K, Papke JB, Kopp ND, Chen J
et al.
Human iPSC-Derived Neurons and Cerebral Organoids Establish
Differential Effects of Germline NF1 Gene Mutations.
Stem Cell Reports
2020; 14:
541–550.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7160375</ArticleId>
            <ArticleId IdType="pubmed">32243842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wegscheid ML, Anastasaki C, Gutmann DH. Human stem cell modeling in neurofibromatosis type 1
(NF1). Exp Neurol
2018; 299:
270–280.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5630478</ArticleId>
            <ArticleId IdType="pubmed">28392281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mo J, Anastasaki C, Chen Z, Shipman T, Papke J, Yin K
et al.
Humanized neurofibroma model from induced pluripotent stem cells
delineates tumor pathogenesis and developmental origins.
J Clin Invest
2021; 131.</Citation>
        </Reference>
        <Reference>
          <Citation>Williams KB, Largaespada DA. New Model Systems and the Development of Targeted
Therapies for the Treatment of Neurofibromatosis Type 1-Associated Malignant
Peripheral Nerve Sheath Tumors. Genes (Basel)
2020; 11.</Citation>
        </Reference>
        <Reference>
          <Citation>Zou C, Smith KD, Liu J, Lahat G, Myers S, Wang WL
et al.
Clinical, pathological, and molecular variables predictive of
malignant peripheral nerve sheath tumor outcome. Ann Surg
2009; 249:
1014–1022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19474676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dasgupta B, Yi Y, Chen DY, Weber JD, Gutmann DH. Proteomic analysis reveals hyperactivation of the
mammalian target of rapamycin pathway in neurofibromatosis 1-associated
human and mouse brain tumors. Cancer Res
2005; 65:
2755–2760.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15805275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K. The NF1 tumor suppressor critically regulates TSC2 and
mTOR. Proc Natl Acad Sci U S A
2005; 102:
8573–8578.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1142482</ArticleId>
            <ArticleId IdType="pubmed">15937108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and
Disease. Cell
2017; 168:
960–976.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5394987</ArticleId>
            <ArticleId IdType="pubmed">28283069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Endo M, Yamamoto H, Setsu N, Kohashi K, Takahashi Y, Ishii T
et al.
Prognostic significance of AKT/mTOR and MAPK pathways and
antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant
peripheral nerve sheath tumors. Clin Cancer Res
2013; 19:
450–461.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23209032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bradtmoller M, Hartmann C, Zietsch J, Jaschke S, Mautner VF, Kurtz A
et al.
Impaired Pten expression in human malignant peripheral nerve
sheath tumours. PLoS One
2012; 7: e47595.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3490977</ArticleId>
            <ArticleId IdType="pubmed">23139750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Misra JR, Irvine KD. The Hippo Signaling Network and Its Biological
Functions. Annu Rev Genet
2018; 52:
65–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6322405</ArticleId>
            <ArticleId IdType="pubmed">30183404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu LMN, Deng Y, Wang J, Zhao C, Wang J, Rao R
et al.
Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives
Malignant Peripheral Nerve Sheath Tumorigenesis.
Cancer Cell
2018; 33: 292–308
e297.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5813693</ArticleId>
            <ArticleId IdType="pubmed">29438698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Isfort I, Elges S, Cyra M, Berthold R, Renner M, Mechtersheimer G
et al.
Prevalence of the Hippo Effectors YAP1/TAZ in Tumors of Soft
Tissue and Bone. Sci Rep
2019; 9: 19704.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6928161</ArticleId>
            <ArticleId IdType="pubmed">31873172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katoh M. Canonical and non-canonical WNT signaling in cancer stem
cells and their niches: Cellular heterogeneity, omics reprogramming,
targeted therapy and tumor plasticity (Review). Int J Oncol
2017; 51:
1357–1369.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5642388</ArticleId>
            <ArticleId IdType="pubmed">29048660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luscan A, Shackleford G, Masliah-Planchon J, Laurendeau I, Ortonne N, Varin J
et al.
The activation of the WNT signaling pathway is a Hallmark in
neurofibromatosis type 1 tumorigenesis. Clin Cancer Res
2014; 20:
358–371.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24218515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thomson CS, Pundavela J, Perrino MR, Coover RA, Choi K, Chaney KE
et al.
WNT5A inhibition alters the malignant peripheral nerve sheath
tumor microenvironment and enhances tumor growth.
Oncogene
2021; 40:
4229–4241.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8217297</ArticleId>
            <ArticleId IdType="pubmed">34079083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF. Neurofibromas in NF1: Schwann cell origin and role of
tumor environment. Science
2002; 296:
920–922.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3024710</ArticleId>
            <ArticleId IdType="pubmed">11988578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang FC, Ingram DA, Chen S, Zhu Y, Yuan J, Li X
et al.
Nf1-dependent tumors require a microenvironment containing
Nf1+/−- and c-kit-dependent bone marrow.
Cell
2008; 135:
437–448.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2788814</ArticleId>
            <ArticleId IdType="pubmed">18984156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J, Williams JP, Rizvi TA, Kordich JJ, Witte D, Meijer D
et al.
Plexiform and dermal neurofibromas and pigmentation are caused by
Nf1 loss in desert hedgehog-expressing cells. Cancer Cell
2008; 13:
105–116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2846699</ArticleId>
            <ArticleId IdType="pubmed">18242511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scaife CL, Pisters PW. Combined-modality treatment of localized soft tissue
sarcomas of the extremities. Surg Oncol Clin N Am
2003; 12:
355–368.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12916459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta G, Mammis A, Maniker A. Malignant peripheral nerve sheath
tumors. Neurosurg Clin N Am
2008; 19:
533–543, v.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19010279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin E, Coert JH, Flucke UE, Slooff WM, van de Sande MAJ, van Noesel MM
et al.
Neurofibromatosis-associated malignant peripheral nerve sheath
tumors in children have a worse prognosis: A nationwide cohort
study. Pediatr Blood Cancer
2020; 67: e28138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31889416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garozzo D
Peripheral nerve tumors in neurofibromatosis 1: An overview on
management and indications for surgical treatment in our
experience. Neurol India
2019; 67:
S38–S44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30688231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferner RE, Golding JF, Smith M, Calonje E, Jan W, Sanjayanathan V
et al.
[18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG
PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant
peripheral nerve sheath tumours (MPNSTs): a long-term clinical
study. Ann Oncol
2008; 19:
390–394.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17932395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mautner VF, Friedrich RE, von Deimling A, Hagel C, Korf B, Knofel MT
et al.
Malignant peripheral nerve sheath tumours in neurofibromatosis
type 1: MRI supports the diagnosis of malignant plexiform
neurofibroma. Neuroradiology
2003; 45:
618–625.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12898075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suratwala SJ, Kondra K, Cronin M, Leone V. Malignant peripheral nerve sheath tumor of the sciatic
nerve presenting with leg pain in the setting of lumbar scoliosis and spinal
stenosis. Spine Deform
2020; 8:
333–338.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31925758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferner RE, Lucas JD, O’Doherty MJ, Hughes RA, Smith MA, Cronin BF
et al.
Evaluation of (18)fluorodeoxyglucose positron emission tomography
((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours
arising from within plexiform neurofibromas in neurofibromatosis
1. J Neurol Neurosurg Psychiatry
2000; 68:
353–357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1736834</ArticleId>
            <ArticleId IdType="pubmed">10675220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Widemann BC, Italiano A. Biology and Management of Undifferentiated Pleomorphic
Sarcoma, Myxofibrosarcoma, and Malignant Peripheral Nerve Sheath Tumors:
State of the Art and Perspectives. J Clin Oncol
2018; 36:
160–167.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5759316</ArticleId>
            <ArticleId IdType="pubmed">29220302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tovmassian D, Abdul Razak M, London K. The Role of [(18)F]FDG-PET/CT in Predicting Malignant
Transformation of Plexiform Neurofibromas in
Neurofibromatosis-1. Int J Surg Oncol
2016; 2016:
6162182.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5183794</ArticleId>
            <ArticleId IdType="pubmed">28058117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahlawat S, Blakeley JO, Langmead S, Belzberg AJ, Fayad LM. Current status and recommendations for imaging in
neurofibromatosis type 1, neurofibromatosis type 2, and
schwannomatosis. Skeletal Radiol
2020; 49:
199–219.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31396668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferner RE, Gutmann DH. International consensus statement on malignant
peripheral nerve sheath tumors in neurofibromatosis.
Cancer Res
2002; 62:
1573–1577.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11894862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dunn GP, Spiliopoulos K, Plotkin SR, Hornicek FJ, Harmon DC, Delaney TF
et al.
Role of resection of malignant peripheral nerve sheath tumors in
patients with neurofibromatosis type 1. J Neurosurg
2013; 118:
142–148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23101443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gachiani J, Kim D, Nelson A, Kline D. Surgical management of malignant peripheral nerve sheath
tumors. Neurosurg Focus
2007; 22: E13.</Citation>
        </Reference>
        <Reference>
          <Citation>Levi AD, Ross AL, Cuartas E, Qadir R, Temple HT. The surgical management of symptomatic peripheral nerve
sheath tumors. Neurosurgery
2010; 66:
833–840.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20190660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang JC, Chang AE, Baker AR, Sindelar WF, Danforth DN, Topalian SL
et al.
Randomized prospective study of the benefit of adjuvant radiation
therapy in the treatment of soft tissue sarcomas of the
extremity. J Clin Oncol
1998; 16:
197–203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9440743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Sullivan B, Davis AM, Turcotte R, Bell R, Catton C, Chabot P
et al.
Preoperative versus postoperative radiotherapy in soft-tissue
sarcoma of the limbs: a randomised trial.
Lancet
2002; 359:
2235–2241.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12103287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kahn J, Gillespie A, Tsokos M, Ondos J, Dombi E, Camphausen K
et al.
Radiation therapy in management of sporadic and neurofibromatosis
type 1-associated malignant peripheral nerve sheath tumors.
Front Oncol
2014; 4: 324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4233912</ArticleId>
            <ArticleId IdType="pubmed">25452937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arshi A, Tajudeen BA, St John M. Malignant peripheral nerve sheath tumors of the head and
neck: Demographics, clinicopathologic features, management, and treatment
outcomes. Oral Oncol
2015; 51:
1088–1094.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26442813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kar M, Deo SV, Shukla NK, Malik A, DattaGupta S, Mohanti BK
et al.
Malignant peripheral nerve sheath tumors
(MPNST)--clinicopathological study and treatment outcome of twenty-four
cases. World J Surg Oncol
2006; 4: 55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1560134</ArticleId>
            <ArticleId IdType="pubmed">16923196</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhatia S, Chen Y, Wong FL, Hageman L, Smith K, Korf B
et al.
Subsequent Neoplasms After a Primary Tumor in Individuals With
Neurofibromatosis Type 1. J Clin Oncol
2019; 37:
3050–3058.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6839906</ArticleId>
            <ArticleId IdType="pubmed">31532722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakamura JL, Phong C, Pinarbasi E, Kogan SC, Vandenberg S, Horvai AE
et al.
Dose-dependent effects of focal fractionated irradiation on
secondary malignant neoplasms in Nf1 mutant mice.
Cancer Res
2011; 71:
106–115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3077533</ArticleId>
            <ArticleId IdType="pubmed">21199799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chou D, Bilsky MH, Luzzati A, Fisher CG, Gokaslan ZL, Rhines LD
et al.
Malignant peripheral nerve sheath tumors of the spine: results of
surgical management from a multicenter study. J Neurosurg Spine
2017; 26:
291–298.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27834629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrari A, Miceli R, Rey A, Oberlin O, Orbach D, Brennan B
et al.
Non-metastatic unresected paediatric non-rhabdomyosarcoma soft
tissue sarcomas: results of a pooled analysis from United States and
European groups. Eur J Cancer
2011; 47:
724–731.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3539303</ArticleId>
            <ArticleId IdType="pubmed">21145727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tierney JF. Adjuvant chemotherapy for localised resectable
soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma
Meta-analysis Collaboration. Lancet
1997; 350:
1647–1654.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9400508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Higham CS, Steinberg SM, Dombi E, Perry A, Helman LJ, Schuetze SM
et al.
SARC006: Phase II Trial of Chemotherapy in Sporadic and
Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral
Nerve Sheath Tumors. Sarcoma
2017; 2017:
8685638.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5613633</ArticleId>
            <ArticleId IdType="pubmed">29138631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carli M, Ferrari A, Mattke A, Zanetti I, Casanova M, Bisogno G
et al.
Pediatric malignant peripheral nerve sheath tumor: the Italian
and German soft tissue sarcoma cooperative group. J Clin Oncol
2005; 23:
8422–8430.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16293873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hubbard SR, Miller WT. Receptor tyrosine kinases: mechanisms of activation and
signaling. Curr Opin Cell Biol
2007; 19:
117–123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2536775</ArticleId>
            <ArticleId IdType="pubmed">17306972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine
kinases. Cell
2010; 141:
1117–1134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2914105</ArticleId>
            <ArticleId IdType="pubmed">20602996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Butti R, Das S, Gunasekaran VP, Yadav AS, Kumar D, Kundu GC. Receptor tyrosine kinases (RTKs) in breast cancer:
signaling, therapeutic implications and challenges.
Mol Cancer
2018; 17: 34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5817867</ArticleId>
            <ArticleId IdType="pubmed">29455658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Regad T
Targeting RTK Signaling Pathways in Cancer.
Cancers (Basel)
2015; 7:
1758–1784.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4586793</ArticleId>
            <ArticleId IdType="pubmed">26404379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chugh R, Wathen JK, Maki RG, Benjamin RS, Patel SR, Meyers PA
et al.
Phase II multicenter trial of imatinib in 10 histologic subtypes
of sarcoma using a bayesian hierarchical statistical model.
J Clin Oncol
2009; 27:
3148–3153.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19451433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schuetze SM, Wathen JK, Lucas DR, Choy E, Samuels BL, Staddon AP
et al.
SARC009: Phase 2 study of dasatinib in patients with previously
treated, high-grade, advanced sarcoma.
Cancer
2016; 122:
868–874.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26710211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li H, Velasco-Miguel S, Vass WC, Parada LF, DeClue JE. Epidermal growth factor receptor signaling pathways are
associated with tumorigenesis in the Nf1:p53 mouse tumor
model. Cancer Res
2002; 62:
4507–4513.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12154062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tabone-Eglinger S, Bahleda R, Cote JF, Terrier P, Vidaud D, Cayre A
et al.
Frequent EGFR Positivity and Overexpression in High-Grade Areas
of Human MPNSTs. Sarcoma
2008; 2008:
849156.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2526168</ArticleId>
            <ArticleId IdType="pubmed">18769552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albritton KH, Rankin C, Coffin CM, Ratner N, Budd GT, Schuetze SM
et al.
Phase II study of erlotinib in metastatic or unresectable
malignant peripheral nerve sheath tumors (MPNST).
Journal of Clinical Oncology
2006; 24:
9518–9518.</Citation>
        </Reference>
        <Reference>
          <Citation>Widemann BC, Lu Y, Reinke D, Okuno SH, Meyer CF, Cote GM
et al.
Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related
Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II
Study of Everolimus in Combination with Bevacizumab
(SARC016). Sarcoma
2019; 2019:
7656747.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6681622</ArticleId>
            <ArticleId IdType="pubmed">31427883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohba Y, Mochizuki N, Yamashita S, Chan AM, Schrader JW, Hattori S
et al.
Regulatory proteins of R-Ras, TC21/R-Ras2, and
M-Ras/R-Ras3. J Biol Chem
2000; 275:
20020–20026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10777492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cox AD, Der CJ. Ras history: The saga continues.
Small GTPases
2010; 1:
2–27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3109476</ArticleId>
            <ArticleId IdType="pubmed">21686117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ratner N, Miller SJ. A RASopathy gene commonly mutated in cancer: the
neurofibromatosis type 1 tumour suppressor. Nat Rev Cancer
2015; 15:
290–301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4822336</ArticleId>
            <ArticleId IdType="pubmed">25877329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP
affinity and effector interactions. Nature
2013; 503:
548–551.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4274051</ArticleId>
            <ArticleId IdType="pubmed">24256730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim HA, Ling B, Ratner N. Nf1-deficient mouse Schwann cells are angiogenic and
invasive and can be induced to hyperproliferate: reversion of some
phenotypes by an inhibitor of farnesyl protein transferase.
Mol Cell Biol
1997; 17:
862–872.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC231813</ArticleId>
            <ArticleId IdType="pubmed">9001241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wojtkowiak JW, Fouad F, LaLonde DT, Kleinman MD, Gibbs RA, Reiners JJ Jr.
et al.
Induction of apoptosis in neurofibromatosis type 1 malignant
peripheral nerve sheath tumor cell lines by a combination of novel farnesyl
transferase inhibitors and lovastatin. J Pharmacol Exp Ther
2008; 326:
1–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3768167</ArticleId>
            <ArticleId IdType="pubmed">18367665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Widemann BC, Salzer WL, Arceci RJ, Blaney SM, Fox E, End D
et al.
Phase I trial and pharmacokinetic study of the
farnesyltransferase inhibitor tipifarnib in children with refractory solid
tumors or neurofibromatosis type I and plexiform
neurofibromas. J Clin Oncol
2006; 24:
507–516.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16421428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Widemann BC, Dombi E, Gillespie A, Wolters PL, Belasco J, Goldman S
et al.
Phase 2 randomized, flexible crossover, double-blinded,
placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in
children and young adults with neurofibromatosis type 1 and progressive
plexiform neurofibromas. Neuro Oncol
2014; 16:
707–718.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3984559</ArticleId>
            <ArticleId IdType="pubmed">24500418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morrison DK. MAP kinase pathways. Cold Spring Harb Perspect Biol
2012; 4.</Citation>
        </Reference>
        <Reference>
          <Citation>Ambrosini G, Cheema HS, Seelman S, Teed A, Sambol EB, Singer S
et al.
Sorafenib inhibits growth and mitogen-activated protein kinase
signaling in malignant peripheral nerve sheath cells.
Mol Cancer Ther
2008; 7:
890–896.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3267321</ArticleId>
            <ArticleId IdType="pubmed">18413802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maki RG, D’Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD
et al.
Phase II study of sorafenib in patients with metastatic or
recurrent sarcomas. J Clin Oncol
2009; 27:
3133–3140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2716936</ArticleId>
            <ArticleId IdType="pubmed">19451436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jessen WJ, Miller SJ, Jousma E, Wu J, Rizvi TA, Brundage ME
et al.
MEK inhibition exhibits efficacy in human and mouse
neurofibromatosis tumors. J Clin Invest
2013; 123:
340–347.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3533264</ArticleId>
            <ArticleId IdType="pubmed">23221341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Markham A, Keam SJ. Selumetinib: First Approval.
Drugs
2020; 80:
931–937.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32504375</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagabushan S, Lau LMS, Barahona P, Wong M, Sherstyuk A, Marshall GM
et al.
Efficacy of MEK inhibition in a recurrent malignant peripheral
nerve sheath tumor. NPJ Precis Oncol
2021; 5: 9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7881142</ArticleId>
            <ArticleId IdType="pubmed">33580196</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johansson G, Mahller YY, Collins MH, Kim MO, Nobukuni T, Perentesis J
et al.
Effective in vivo targeting of the mammalian target of rapamycin
pathway in malignant peripheral nerve sheath tumors.
Mol Cancer Ther
2008; 7:
1237–1245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2855168</ArticleId>
            <ArticleId IdType="pubmed">18483311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weiss B, Widemann BC, Wolters P, Dombi E, Vinks A, Cantor A
et al.
Sirolimus for progressive neurofibromatosis type 1-associated
plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium
phase II study. Neuro Oncol
2015; 17:
596–603.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4483073</ArticleId>
            <ArticleId IdType="pubmed">25314964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varin J, Poulain L, Hivelin M, Nusbaum P, Hubas A, Laurendeau I
et al.
Dual mTORC1/2 inhibition induces anti-proliferative effect in
NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath
tumor cells. Oncotarget
2016; 7:
35753–35767.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5094959</ArticleId>
            <ArticleId IdType="pubmed">26840085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watson AL, Anderson LK, Greeley AD, Keng VW, Rahrmann EP, Halfond AL
et al.
Cotargeting the MAPK and PI3K/AKT/mTOR pathways in two
genetically engineered mouse models of schwann cell tumors reduces tumor
grade and multiplicity. Oncotarget
2014; 5:
1502–1514.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4039227</ArticleId>
            <ArticleId IdType="pubmed">24681606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim A, Lu Y, Okuno SH, Reinke D, Maertens O, Perentesis J
et al.
Targeting Refractory Sarcomas and Malignant Peripheral Nerve
Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with
Ganetespib (SARC023). Sarcoma
2020; 2020:
5784876.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7013290</ArticleId>
            <ArticleId IdType="pubmed">32089640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malone CF, Emerson C, Ingraham R, Barbosa W, Guerra S, Yoon H
et al.
mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin
Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven
Tumors. Cancer Discov
2017; 7:
1450–1463.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5718976</ArticleId>
            <ArticleId IdType="pubmed">28963352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kohlmeyer JL, Kaemmer CA, Pulliam C, Maharjan CK, Samayoa AM, Major HJ
et al.
RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates
the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6
Inhibitors. Clin Cancer Res
2020; 26:
2997–3011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7299809</ArticleId>
            <ArticleId IdType="pubmed">32086342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cleven AH, Sannaa GA, Briaire-de Bruijn I, Ingram DR, van de Rijn M, Rubin BP
et al.
Loss of H3K27 tri-methylation is a diagnostic marker for
malignant peripheral nerve sheath tumors and an indicator for an inferior
survival. Mod Pathol
2016; 29:
582–590.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4948583</ArticleId>
            <ArticleId IdType="pubmed">26990975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo J, Chaney KE, Choi K, Witek G, Patel AV, Xie H
et al.
Polo-like kinase 1 as a therapeutic target for malignant
peripheral nerve sheath tumors (MPNST) and schwannomas.
Am J Cancer Res
2020; 10:
856–869.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7136923</ArticleId>
            <ArticleId IdType="pubmed">32266095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Williams KB, Williams RL, Rathe SK, Hawkinson J, Largaespada DA. Abstract A37: Synthetic lethality as a tool to reveal
novel vulnerabilities in NF1-associated tumorigenesis.
Molecular Cancer Therapeutics
2017; 16:
A37–A37.</Citation>
        </Reference>
        <Reference>
          <Citation>Castells-Roca L, Tejero E, Rodriguez-Santiago B, Surralles J. CRISPR Screens in Synthetic Lethality and Combinatorial
Therapies for Cancer. Cancers (Basel)
2021; 13.</Citation>
        </Reference>
        <Reference>
          <Citation>Semenova G, Stepanova DS, Deyev SM, Chernoff J. Medium throughput biochemical compound screening
identifies novel agents for pharmacotherapy of neurofibromatosis type
1. Biochimie
2017; 135:
1–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5405558</ArticleId>
            <ArticleId IdType="pubmed">28065690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wood M, Rawe M, Johansson G, Pang S, Soderquist RS, Patel AV
et al.
Discovery of a small molecule targeting IRA2 deletion in budding
yeast and neurofibromin loss in malignant peripheral nerve sheath tumor
cells. Mol Cancer Ther
2011; 10:
1740–1750.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3170489</ArticleId>
            <ArticleId IdType="pubmed">21697395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kahen EJ, Brohl A, Yu D, Welch D, Cubitt CL, Lee JK
et al.
Neurofibromin level directs RAS pathway signaling and mediates
sensitivity to targeted agents in malignant peripheral nerve sheath
tumors. Oncotarget
2018; 9:
22571–22585.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5978249</ArticleId>
            <ArticleId IdType="pubmed">29854299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cooper JM, Patel AJ, Chen Z, Liao CP, Chen K, Mo J
et al.
Overcoming BET Inhibitor Resistance in Malignant Peripheral Nerve
Sheath Tumors. Clin Cancer Res
2019; 25:
3404–3416.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6548569</ArticleId>
            <ArticleId IdType="pubmed">30796033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mashour GA, Drissel SN, Frahm S, Farassati F, Martuza RL, Mautner VF
et al.
Differential modulation of malignant peripheral nerve sheath
tumor growth by omega-3 and omega-6 fatty acids.
Oncogene
2005; 24:
2367–2374.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15735744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lopez G, Torres K, Liu J, Hernandez B, Young E, Belousov R
et al.
Autophagic survival in resistance to histone deacetylase
inhibitors: novel strategies to treat malignant peripheral nerve sheath
tumors. Cancer Res
2011; 71:
185–196.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3064267</ArticleId>
            <ArticleId IdType="pubmed">21084276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reuss DE, Mucha J, Hagenlocher C, Ehemann V, Kluwe L, Mautner V
et al.
Sensitivity of malignant peripheral nerve sheath tumor cells to
TRAIL is augmented by loss of NF1 through modulation of MYC/MAD and is
potentiated by curcumin through induction of ROS.
PLoS One
2013; 8: e57152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3578816</ArticleId>
            <ArticleId IdType="pubmed">23437333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahller YY, Vaikunth SS, Ripberger MC, Baird WH, Saeki Y, Cancelas JA
et al.
Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus
inhibits tumor growth and vascular progenitors.
Cancer Res
2008; 68:
1170–1179.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2855837</ArticleId>
            <ArticleId IdType="pubmed">18281493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, Rao PK, Wen R, Song Y, Muir D, Wallace P
et al.
Notch and Schwann cell transformation.
Oncogene
2004; 23:
1146–1152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14762442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Glover TW, Stein CK, Legius E, Andersen LB, Brereton A, Johnson S. Molecular and cytogenetic analysis of tumors in von
Recklinghausen neurofibromatosis. Genes Chromosomes Cancer
1991; 3:
62–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1906341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan N, Ricca C, Fletcher J, Glover T, Seizinger BR, Manne V. Farnesyltransferase inhibitors block the
neurofibromatosis type I (NF1) malignant phenotype.
Cancer Res
1995; 55:
3569–3575.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7627966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mattingly RR, Kraniak JM, Dilworth JT, Mathieu P, Bealmear B, Nowak JE
et al.
The mitogen-activated protein kinase/extracellular
signal-regulated kinase kinase inhibitor PD184352 (CI-1040) selectively
induces apoptosis in malignant schwannoma cell lines.
J Pharmacol Exp Ther
2006; 316:
456–465.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16239399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koelsche C, Renner M, Hartmann W, Brandt R, Lehner B, Waldburger N
et al.
TERT promoter hotspot mutations are recurrent in myxoid
liposarcomas but rare in other soft tissue sarcoma entities.
J Exp Clin Cancer Res
2014; 33: 33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4022359</ArticleId>
            <ArticleId IdType="pubmed">24726063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teicher BA, Polley E, Kunkel M, Evans D, Silvers T, Delosh R
et al.
Sarcoma Cell Line Screen of Oncology Drugs and Investigational
Agents Identifies Patterns Associated with Gene and microRNA
Expression. Mol Cancer Ther
2015; 14:
2452–2462.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4636476</ArticleId>
            <ArticleId IdType="pubmed">26351324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee PR, Cohen JE, Tendi EA, Farrer R, GH DEV, Becker KG
et al.
Transcriptional profiling in an MPNST-derived cell line and
normal human Schwann cells. Neuron Glia Biol
2004; 1:
135–147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1325299</ArticleId>
            <ArticleId IdType="pubmed">16429615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yi C, Troutman S, Fera D, Stemmer-Rachamimov A, Avila JL, Christian N
et al.
A tight junction-associated Merlin-angiomotin complex mediates
Merlin’s regulation of mitogenic signaling and tumor suppressive
functions. Cancer Cell
2011; 19:
527–540.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3075552</ArticleId>
            <ArticleId IdType="pubmed">21481793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Subramanian S, Thayanithy V, West RB, Lee CH, Beck AH, Zhu S
et al.
Genome-wide transcriptome analyses reveal p53 inactivation
mediated loss of miR-34a expression in malignant peripheral nerve sheath
tumours. J Pathol
2010; 220:
58–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4058327</ArticleId>
            <ArticleId IdType="pubmed">19890883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagashima Y, Ohaki Y, Tanaka Y, Sumino K, Funabiki T, Okuyama T
et al.
Establishment of an epithelioid malignant schwannoma cell line
(YST-1). Virchows Arch B Cell Pathol Incl Mol Pathol
1990; 59:
321–327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1980563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dahlberg WK, Little JB, Fletcher JA, Suit HD, Okunieff P. Radiosensitivity in vitro of human soft tissue sarcoma
cell lines and skin fibroblasts derived from the same
patients. Int J Radiat Biol
1993; 63:
191–198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8094415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sonobe H, Takeuchi T, Furihata M, Taguchi T, Kawai A, Ohjimi Y
et al.
A new human malignant peripheral nerve sheath tumour-cell line,
HS-sch-2, harbouring p53 point mutation. Int J Oncol
2000; 17:
347–352.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10891546</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
